Illumina, Inc. (ILMN) Shares Sold by Ardevora Asset Management LLP

Ardevora Asset Management LLP lessened its stake in Illumina, Inc. (NASDAQ:ILMN) by 15.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 80,262 shares of the life sciences company’s stock after selling 14,350 shares during the quarter. Ardevora Asset Management LLP owned about 0.05% of Illumina worth $29,461,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Frontier Capital Management Co. LLC boosted its holdings in shares of Illumina by 8.1% in the 3rd quarter. Frontier Capital Management Co. LLC now owns 309,339 shares of the life sciences company’s stock valued at $113,546,000 after purchasing an additional 23,221 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of Illumina by 1.0% in the 3rd quarter. Arizona State Retirement System now owns 36,435 shares of the life sciences company’s stock valued at $13,374,000 after purchasing an additional 356 shares during the last quarter. Round Table Services LLC acquired a new position in shares of Illumina in the 3rd quarter valued at $222,000. GWM Advisors LLC acquired a new position in shares of Illumina in the 3rd quarter valued at $659,000. Finally, Cim LLC acquired a new position in shares of Illumina in the 3rd quarter valued at $733,000. Institutional investors own 89.87% of the company’s stock.

In related news, EVP Marc Stapley sold 1,000 shares of Illumina stock in a transaction on Thursday, August 2nd. The shares were sold at an average price of $324.80, for a total transaction of $324,800.00. Following the sale, the executive vice president now owns 8,316 shares of the company’s stock, valued at approximately $2,701,036.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Francis A. Desouza sold 2,100 shares of Illumina stock in a transaction on Monday, October 1st. The stock was sold at an average price of $369.61, for a total transaction of $776,181.00. The disclosure for this sale can be found here. Insiders have sold a total of 53,183 shares of company stock worth $17,883,841 in the last 90 days. Company insiders own 0.54% of the company’s stock.

ILMN has been the topic of a number of research analyst reports. Cowen lifted their price target on shares of Illumina from $275.00 to $315.00 and gave the company an “outperform” rating in a report on Tuesday, July 10th. Morgan Stanley lifted their price target on shares of Illumina from $195.00 to $210.00 and gave the company an “underweight” rating in a report on Friday, July 13th. Piper Jaffray Companies lifted their price target on shares of Illumina from $272.00 to $329.00 and gave the company an “overweight” rating in a report on Tuesday, July 17th. Canaccord Genuity reiterated a “buy” rating and issued a $340.00 price target (up previously from $330.00) on shares of Illumina in a report on Friday, July 27th. Finally, Barclays lifted their price target on shares of Illumina from $300.00 to $350.00 and gave the company an “overweight” rating in a report on Tuesday, July 31st. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $330.94.

NASDAQ:ILMN opened at $303.75 on Wednesday. The company has a current ratio of 2.46, a quick ratio of 2.24 and a debt-to-equity ratio of 0.24. The firm has a market cap of $43.38 billion, a P/E ratio of 75.94, a price-to-earnings-growth ratio of 2.19 and a beta of 0.97. Illumina, Inc. has a twelve month low of $203.39 and a twelve month high of $372.61.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.26 by $0.26. The business had revenue of $853.00 million for the quarter, compared to analyst estimates of $825.65 million. Illumina had a net margin of 21.09% and a return on equity of 27.10%. The business’s quarterly revenue was up 19.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.11 EPS. Sell-side analysts forecast that Illumina, Inc. will post 5.75 EPS for the current year.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Read More: Buyback For Investors Defined

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply